Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

Seres Therapeutics (MCRB) Equity Ratio (2016 - 2025)

Seres Therapeutics (MCRB) has disclosed Equity Ratio for 11 consecutive years, with 0.32 as the latest value for Q4 2025.

  • Quarterly Equity Ratio rose 224.55% to 0.32 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.32 through Dec 2025, up 224.55% year-over-year, with the annual reading at 0.32 for FY2025, 224.55% up from the prior year.
  • Equity Ratio hit 0.32 in Q4 2025 for Seres Therapeutics, up from 0.3 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.47 in Q1 2021 to a low of 0.27 in Q2 2024.
  • Historically, Equity Ratio has averaged 0.15 across 5 years, with a median of 0.18 in 2022.
  • Biggest YoY gain for Equity Ratio was 425.37% in 2024; the steepest drop was 586.36% in 2024.
  • Year by year, Equity Ratio stood at 0.37 in 2021, then plummeted by 91.66% to 0.03 in 2022, then tumbled by 504.6% to 0.13 in 2023, then surged by 178.82% to 0.1 in 2024, then skyrocketed by 224.55% to 0.32 in 2025.
  • Business Quant data shows Equity Ratio for MCRB at 0.32 in Q4 2025, 0.3 in Q3 2025, and 0.23 in Q2 2025.